M&A Already Underway As Angelini Acquires Arvelle

Will Commercialize Epilepsy Drug Cenobamate In Europe

 
• By Kevin Grogan

2020 has kicked off with a major European biotech deal that will see the Italian conglomerate Angelini take over Switzerland's Arvelle which is on the verge of getting EU approval for an anti-epilepsy drug licensed from SK Bio that got the green light in the US two years ago.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal.
Angelini And Arvelle Look To Bridge Gaps In Epilepsy Market • Source: Archive

More from Deals

More from Business